Comorbidity between temporal lobe epilepsy and depression: A [ 18F]MPPF PET study

Brain

Volumn 131, Issue 10, 2008, Pages 2765-2782

  Lothe, A ^a   Didelot, A ^a   Hammers, A ^b   Costes, N ^a   Saoud, M ^a   Gilliam, F ^c   Ryvlin, P ^a,d  

^a UNIVERSITÉ LYON 1   (France)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d HÔPITAL NEUROLOGIQUE   (France)

Author keywords

18F MPPF; Depressive symptoms; TLE

Indexed keywords

ANTIDEPRESSANT AGENT; MPPF F 18; TRACER; UNCLASSIFIED DRUG;

ADULT; ANHEDONIA; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; COGNITION; COMORBIDITY; DEPRESSION; FEMALE; HIPPOCAMPAL SCLEROSIS; HUMAN; INSULA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAPHE NUCLEUS; SCORING SYSTEM; SYMPTOM; TEMPORAL LOBE EPILEPSY;

ADULT; AMINOPYRIDINES; BRAIN; CEREBRAL CORTEX; DEPRESSION; EPILEPSY, TEMPORAL LOBE; FEMALE; FLUORODEOXYGLUCOSE F18; HIPPOCAMPUS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; RAPHE NUCLEI; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN;

EID: 54949105109     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awn194     Document Type: Article

References (102)

1. Ahmad S, Fowler LJ, Whitton PS. Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat. Br J Pharmacol 2004; 142: 136-42.
2. Ahmad S, Fowler LJ, Whitton PS. Lamotrigine, carbamazepine and phenytoin differentially alter extracellular levels of 5-hydroxytryptamine, dopamine and amino acids. Epilepsy Res 2005; 63: 141-9.
3. Altshuler LL, Devinsky O, Post RM, Theodore W. Depression, anxiety, and temporal lobe epilepsy. Laterality of focus and symptoms. Arch Neurol 1990; 47: 284-8.
4. Anderson AD, Oquendo MA, Parsey RV, Milak MS, Campbell C, Mann JJ. Regional brain responses to serotonin in major depressive disorder. J Affect Disord 2004; 82: 411-7.
5. Arango V, Underwood MD, Boldrini M, Tamir H, Kassir SA, Hsiung S, et al. Serotonin 1A receptors, serotonin transporter binding and serotonin transporter mRNA expression in the brainstem of depressed suicide victims. Neuropsychopharmacology 2001; 25: 892-903.
6. Asberg M, Thoren P, Traskman L, Bertilsson L, Ringberger V. 'Serotonin depression'-a biochemical subgroup within the affective disorders? Science 1976; 191: 478-80.
7. Barba C, Barbati G, Minotti L, Hoffmann D, Kahane P. Ictal clinical and scalp-EEG findings differentiating temporal lobe epilepsies from temporal 'plus' epilepsies. Brain 2007; 130 (Pt 7): 1957-67.
8. Baxendale SA, Thompson PJ, Duncan JS. Epilepsy & depression: the effects of comorbidity on hippocampal volume-a pilot study. Seizure 2005; 14: 435-8.
9. Bench CJ, Friston KJ, Brown RG, Frackowiak RS, Dolan RJ. Regional cerebral blood flow in depression measured by positron emission tomography: the relationship with clinical dimensions. Psychol Med 1993; 23: 579-90.
10. Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry 2004; 9: 386-92.
11. Boldrini M, Underwood MD, Mann JJ, Arango V. Serotonin-1A autoreceptor binding in the dorsal raphe nucleus of depressed suicides. J Psychiatr Res 2008; 42: 433-42.
12. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. Am J Psychiatry 2000; 157: 115-8.
13. Briellmann RS, Hopwood MJ, Jackson GD. Major depression in temporal lobe epilepsy with hippocampal sclerosis: clinical and imaging correlates. J Neurol Neurosurg Psychiatry 2007; 78: 1226-30.
14. Cathébras P, Mosnier C, Lévy M, Bouchou K, Rousset H. Screening for depression in patients with medical hospitalization. Comparison of two self-evaluation scales and clinical assessment with a structured questionnaire. Encephale 1994; 20: 311-7.
15. Clinckers R, Smolders I, Meurs A, Ebinger G, Michotte Y. Hippocampal dopamine and serotonin elevations as pharmacodynamic markers for the anticonvulsant efficacy of oxcarbazepine and 10,11-dihydro-10- hydroxycarbamazepine. Neurosci Lett 2005; 390: 48-53.
16. Costello CG. Research on symptoms versus research on syndromes: arguments in favour of allocating more research time to the study of symptoms. Br J Psychiatry 1992; 160: 304-8.
17. Costes N, Merlet I, Zimmer L, Lavenne F, Cinotti L, Delforge J, et al. Modeling [18F]MPPF positron emission tomography kinetics for the determination of 5-hydroxytryptamine(1A) receptor concentration with multiinjection. J Cereb Blood Flow Metab 2002; 22: 753-65.
18. 18F-MPPF PET normative database of 5-HT1A receptor binding in men and women over aging. J Nucl Med 2005; 46: 1980-9.
19. Dailey JW, Reith ME, Yan QS, Li MY, Jobe PC. Carbamazepine increases extracellular serotonin concentration: lack of antagonism by tetrodotoxin or zero Ca2+. Eur J Pharmacol 1997; 328: 153-62.
20. Dhaenen H. Imaging the serotonergic system in depression. Eur Arch Psychiatry Clin Neurosci 2001; 251 (Suppl 2): II76-80.
21. Drevets WC. Neuroimaging studies of mood disorders. Biol Psychiatry 2000; 48: 813-29.
22. Drevets WC, Bogers W, Raichle ME. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur Neuropsychopharmacol 2002; 12: 527-44.
23. Drevets WC, Frank E, Price JC, Kupfer DJ, Greer PJ, Mathis C. Serotonin type-1A receptor imaging in depression. Nucl Med Biol 2000; 27: 499-507.
24. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry 1999; 46: 1375-87.
25. Drevets WC, Thase ME, Moses-Kolko EL, Price J, Frank E, Kupfer DJ, et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol 2007; 34: 865-77.
26. Dunn RT, Kimbrell TA, Ketter TA, Frye MA, Willis MW, Luckenbaugh DA, et al. Principal components of the Beck Depression Inventory and regional cerebral metabolism in unipolar and bipolar depression. Biol Psychiatry 2002; 51: 387-99.
27. Engel J Jr. Classifications of the international league against epilepsy: time for reappraisal. Epilepsia 1998; 39: 1014-7.
28. Fitzgerald PB, Laird AR, Maller J, Daskalakis ZJ. A meta-analytic study of changes in brain activation in depression. Hum Brain Mapp 2008; 29: 683-95.
29. Friston KJ, Frith CD, Liddle PF, Frackowiak RSJ. Comparing functional (PET) images: the assessment of significant changes. J Cereb Blood Flow Metab 1991; 11: 690-9.
30. Friston KJ, Holmes AP, Worsley KJ, Poline JB, Frith CD, Frackowiak RJS. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995; 3: 189-210.
31. Frodl T, Meisenzahl EM, Zetzsche T, Born C, Groll C, Jager M, et al. Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry 2002; 159: 1112-8.
32. Gilliam FG, Maton BM, Martin RC, Sawrie SM, Faught RE, Hugg JW, et al. Hippocampal 1H-MRSI correlates with severity of depression symptoms in temporal lobe epilepsy. Neurology 2007; 68: 364-8.
33. Giovacchini G, Toczek MT, Bonwetsch R, Bagic A, Lang L, Fraser C, et al. 5-HT 1A receptors are reduced in temporal lobe epilepsy after partial-volume correction. J Nucl Med 2005; 46: 1128-35.
34. Graff-Guerrero A, Gonzalez-Olvera J, Mendoza-Espinosa Y, Vaugier V, Garcia-Reyna JC. Correlation between cerebral blood flow and items of the Hamilton Rating Scale for Depression in antidepressant-naive patients. J Affect Disord 2004; 80: 55-63.
35. Gunn RN, Sargent PA, Bench CJ, Rabiner EA, Osman S, Pike VW, et al. Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY- 100635 for PET. Neuroimage 1998; 8: 426-40.
36. Hammers A, Asselin MC, Hinz R, Kitchen I, Brooks DJ, Duncan JS, et al. Upregulation of opioid receptor binding following spontaneous epileptic seizures. Brain 2007; 130: 1009-16.
37. Hammers A, Koepp MJ, Hurlemann R, Thom M, Richardson MP, Brooks DJ, et al. Abnormalities of grey and white matter [11C]flumazenil binding in temporal lobe epilepsy with normal MRI. Brain 2002; 125: 2257-71.
38. Hammers A, Koepp MJ, Richardson MP, Hurlemann R, Brooks DJ, Duncan JS. Grey and white matter flumazenil binding in neocortical epilepsy with normal MRI. A PET study of 44 patients. Brain 2003; 126 (Pt 6): 1300-18.
39. Hasler G, Bonwetsch R, Giovacchini G, Toczek MT, Bagic A, Luckenbaugh DA, et al. 5-HT(1A) receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry 2007; 62: 1258-64.
40. Hećimović H, Goldstein JD, Sheline YI, Gilliam FG. Mechanisms of depression in epilepsy from a clinical perspective. Epilepsy Behav 2003; 4 (Suppl 3): S25-30.
41. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-39.
42. Isnard J, Guénot M, Ostrowsky K, Sindou M, Mauguière F. The role of the insular cortex in temporal lobe epilepsy. Ann Neurol 2000; 48: 614-23.
43. Ito S, Suhara T, Ito H, Yasuno F, Ichimiya T, Takano A, et al. Changes in central 5-HT(1A) receptor binding in mesial temporal epilepsy measured by positron emission tomography with [(11)C]WAY100635. Epilepsy Res 2007; 73: 111-8.
44. Jones JE, Hermann BP, Barry JJ, Gilliam F, Kanner AM, Meador KJ. Clinical assessment of axis I psychiatric morbidity in chronic epilepsy: a multicenter investigation. J Neuropsychiatry Clin Neurosci Spring 2005a; 17: 172-9.
45. Jones JE, Hermann BP, Woodard JL, Barry JJ, Gilliam F, Kanner AM, et al. Screening for major depression in epilepsy with common self-report depression inventories. Epilepsia 2005b; 46: 731-5.
46. Jorge RE, Robinson RG, Arndt SV, Forrester AW, Geisler F, Starkstein SE. Comparison between acute- and delayed-onset depression following traumatic brain injury. J Neuropsychiatry Clin Neurosci 1993; 5: 43-9.
47. Kabani M, MacDonald D, Holmes C, Evans A. 3D anatomical atlas of the human brain. Arthur W, Toga RSJF, John CM, editors. In: Proceedings of Fourth International Conference on Functional Mapping of the Human Brain, Montreal, Canada. NeuroImage, Organization for Human Brain Mapping; 1998.
48. Kanner AM. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol Psychiatry 2003; 54: 388-98.
49. Karzmark P, Zeifert P, Barry J. Measurement of depression in epilepsy. Epilepsy Behav 2001; 2: 124-8.
50. Kennedy SH, Evans KR, Kruger S, Mayberg HS, Meyer JH, McCann S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 2001; 158: 899-905.
51. Kimbrell TA, Ketter TA, George MS, Little JT, Benson BE, Willis MW, et al. Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. Biol Psychiatry 2002; 51: 237-52.
52. Kohler C, Norstrand JA, Baltuch G, O'Connor MJ, Gur RE, French JA, et al. Depression in temporal lobe epilepsy before epilepsy surgery. Epilepsia 1999; 40: 336-40.
53. Lehrner J, Kalchmayr R, Serles W, Olbrich A, Pataraia E, Aull S, et al. Health-related quality of life (HRQOL), activity of daily living (ADL) and depressive mood disorder in temporal lobe epilepsy patients. Seizure 1999; 8: 88-92.
54. Lipsey JR, Robinson RG, Pearlson GD, Rao K, Price TR. Mood change following bilateral hemisphere brain injury. Br J Psychiatry 1983; 143: 266-73.
55. Lopez JF, Chalmers DT, Little KY, Watson SJ. A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry 1998; 43: 547-73.
56. Lopez JF, Liberzon I, Vazquez DM, Young EA, Watson SJ. Serotonin 1A receptor messenger RNA regulation in the hippocampus after acute stress. Biol Psychiatry 1999; 45: 934-7.
57. Lopez-Figueroa AL, Norton CS, Lopez-Figueroa MO, Armellini-Dodel D, Burke S, Akil H, et al. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry 2004; 55: 225-33.
58. Mayberg HS. Limbic-cortical dysregulation: a proposed model of depression. J Neuropsychiatry Clin Neurosci 1997; 9: 471-81.
59. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al. Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. Am J Psychiatry 1999; 156: 675-82.
60. Meltzer HY. Role of serotonin in depression. Ann N Y Acad Sci 1990; 600: 486-99.
61. Mendez MF, Cummings JL, Benson DF. Depression in epilepsy: significance and phenomenology. Arch Neurol 1986; 43: 766-70.
62. Merlet I, Ryvlin P, Costes N, Dufournel D, Isnard J, Faillenot I, et al. Statistical parametric mapping of 5-HT1A receptor binding in temporal lobe epilepsy with hippocampal ictal onset on intracranial EEG. Neuroimage 2004a; 22: 886-96.
63. Merlet I, Ostrowsky K, Costes N, Ryvlin P, Isnard J, Faillenot I, et al. 5-HT1A receptor binding and intracerebral activity in temporal lobe epilepsy: an [18F]MPPF-PET study. Brain 2004b; 127 (Pt 4): 900-13.
64. Milak MS, Parsey RV, Keilp J, Oquendo MA, Malone KM, Mann JJ. Neuroanatomic correlates of psychopathologic components of major depressive disorder. Arch Gen Psychiatry 2005; 62: 397-408.
65. Moses-Kolko EL, Price JC, Thase ME, Meltzer CC, Kupfer DJ, Mathis CA, et al. Measurement of 5-HT1A receptor binding in depressed adults before and after antidepressant drug treatment using positron emission tomography and [11C]WAY-100635. Synapse 2007; 61: 523-30.
66. Nagai M, Kishi K, Kato S. Insular cortex and neuropsychiatric disorders: a review of recent literature. Eur Psychiatry 2007; 22: 387-94.
67. Okada M, Kawata Y, Kiryu K, Mizuno K, Wada K, Inomata H, et al. Effects of non-toxic and toxic concentrations of phenytoin on monoamines levels in rat brain. Epilepsy Res 1997; 28: 155-63.
68. Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, Huang YY, et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry 2006; 59: 106-13.
69. Price JL. Prefrontal cortical networks related to visceral function and mood. Ann N Y Acad Sci. 1999; 877: 383-96.
70. Pugsley TA, Whetzel SZ, Dooley DJ. Reduction of 3,4-diaminopyridine- induced biogenic amine synthesis and release in rat brain by gabapentin. Psychopharmacology 1998; 137: 74-80.
71. Quiske A, Helmstaedter C, Lux S, Elger CE. Depression in patients with temporal lobe epilepsy is related to mesial temporal sclerosis. Epilepsy Res 2000; 39: 121-5.
72. Rbah L, Leviel V, Zimmer L. Displacement of the PET ligand 18F-MPPF by the electrically evoked serotonin release in the rat hippocampus. Synapse 2003; 49: 239-45.
73. Richardson EJ, Griffith HR, Martin RC, Paige AL, Stewart CC, Jones J, et al. Structural and functional neuroimaging correlates of depression in temporal lobe epilepsy. Epilepsy Behav 2007; 10: 242-9.
74. Richer M, Hen R, Blier P. Modification of serotonin neuron properties in mice lacking 5-HT1A receptors. Eur J Pharmacol 2002; 435: 195-203.
75. Ring HA, Acton PD, Scull D, Costa DC, Gacinovik S, Trimble MR. Patterns of brain activity in patients with epilepsy and depression. Seizure 1999; 8: 390-7.
76. Robertson MM, Trimble MR, Townsend HR. Phenomenology of depression in epilepsy. Epilepsia 1987; 28: 364-72.
77. Robinson RG, Boston JD, Starkstein SE, Price TR. Comparison of mania and depression after brain injury: causal factors. Am J Psychiatry 1988; 145: 172-8.
78. Robinson RG, Kubos KL, Starr LB, Rao K, Price TR. Mood disorders in stroke patients. importance of location of lesion. Brain 1984; 107 (Pt 1): 81-93.
79. Rosa-Neto P, Diksic M, Okazawa H, Leyton M, Ghadirian N, Mzengeza S, et al. Measurement of brain regional alpha-[11C]methyl-L-tryptophan trapping as a measure of serotonin synthesis in medication-free patients with major depression. Arch Gen Psychiatry 2004; 61: 556-63.
80. Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000; 57: 174-80.
81. Savic I, Lindstrom P, Gulyas B, Halldin C, Andree B, Farde L. Limbic reductions of 5-HT1A receptor binding in human temporal lobe epilepsy. Neurology 2004; 62: 1343-51.
82. Saxena S, Brody AL, Ho ML, Alborzian S, Ho MK, Maidment KM, et al. Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently. Biol Psychiatry 2001; 50: 159-70.
83. Seminowicz DA, Mayberg HS, McIntosh AR, Goldapple K, Kennedy S, Segal Z, et al. Limbic-frontal circuitry in major depression: a path modeling metanalysis. Neuroimage 2004; 22: 409-18.
84. Sheline YI. Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry 2003; 54: 338-52.
85. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry 2003; 160: 1516-8.
86. Shelley BP, Trimble MR. The insular lobe of Reil-its anatamico- functional, behavioural and neuropsychiatric attributes in humans-a review. World J Biol Psychiatry 2004; 5: 176-200.
87. Steer RA, Ball R, Ranieri WF, Beck AT. Dimensions of the Beck Depression Inventory-II in clinically depressed outpatients. J Clin Psychol. 1999; 55: 117-28.
88. Stockmeier CA, Shapiro LA, Dilley GE, Kolli TN, Friedman L, Rajkowska G. Increase in serotonin-1A autoreceptors in the midbrain of suicide victims with major depression-postmortem evidence for decreased serotonin activity. J Neurosci 1998; 18: 7394-401.
89. Sudha S, Lakshmana MK, Pradhan N. Phenobarbital in the anticonvulsant dose range does not impair learning and memory or alter brain AChE activity or monoamine levels. Pharmacol Biochem Behav 1996; 54: 633-8.
90. Sullivan GM, Oquendo MA, Simpson N, Van Heertum RL, Mann JJ, Parsey RV. Brain serotonin1A receptor binding in major depression is related to psychic and somatic anxiety. Biol Psychiatry 2005; 58: 947-54.
91. Takebayashi M, Motohashi N, Saito H, Kagaya A, Yamawaki S. Effect of acute treatment with sodium valproate on catecholamine and serotonin synthesis in mouse cerebral cortex. Neuropsychobiology 1995; 32: 124-7.
92. Tauscher J, Verhoeff NP, Christensen BK, Hussey D, Meyer JH, Kecojevic A, et al. Serotonin 5-HT1A receptor binding potential declines with age as measured by [11C]WAY-100635 and PET. Neuropsychopharmacology 2001; 24: 522-30.
93. Theodore WH, Giovacchini G, Bonwetsch R, Bagic A, Reeves-Tyer P, Herscovitch P, et al. The effect of antiepileptic drugs on 5-HT-receptor binding measured by positron emission tomography. Epilepsia. 2006; 47: 499-503.
94. Theodore WH, Hasler G, Giovacchini G, Kelley K, Reeves-Tyer P, Herscovitch P, et al. Reduced hippocampal 5HT1A PET receptor binding and depression in temporal lobe epilepsy. Epilepsia 2007; 48: 1526-30.
95. Toczek MT, Carson RE, Lang L, Ma Y, Spanaki MV, Der MG, et al. PET imaging of 5-HT1A receptor binding in patients with temporal lobe epilepsy. Neurology 2003; 60: 749-56.
96. Underwood MD, Khaibulina AA, Ellis SP, Moran A, Rice PM, Mann JJ, et al. Morphometry of the dorsal raphe nucleus serotonergic neurons in suicide victims. Biol Psychiatry 1999; 46: 473-83.
97. Victoroff JI, Benson F, Grafton ST, Engel J Jr, Mazziotta JC. Depression in complex partial seizures. electroencephalography and cerebral metabolic correlates. Arch Neurol 1994; 51: 155-63.
98. Videbech P, Ravnkilde B, Pedersen TH, Hartvig H, Egander A, Clemmensen K, et al. The Danish PET/depression project: clinical symptoms and cerebral blood flow. A regions-of-interest analysis. Acta Psychiatr Scand 2002; 106: 35-44.
99. Weissmann-Nanopoulos D, Mach E, Magre S, Demassay Y, Pujol JF. Evidence for the localization of 5HT1-A binding sites on serotonin containing neurons in the raphe dorsalis and raphe centralis nuclei of the rat brain. Neurochem Int 1985; 7: 1061-72.
100. Wieser HG and ILAE Commission on Neurosurgery of Epilepsy. ILAE commission report. Mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsia 2004; 45: 695-714.
101. Zimmer L, Mauger G, Le Bars D, Bonmarchand G, Luxen A, Pujol JF. Effect of endogenous serotonin on the binding of the 5-hT1A PET ligand 18F-MPPF in the rat hippocampus: kinetic beta measurements combined with microdialysis. J Neurochem. 2002; 80: 278-86.
102. Zhuang ZP, Kung MP, Chumpradit S, Mu M, Kung HF. Derivatives of 4-(2′-methoxyphenyl)-1-[2′-(N-2″-pyridinyl-p-iodobenzamido) ethyl] pipera zine (p-MPPI) as 5-HT1A ligands. J Med Chem 1994; 37: 4572-5.